Penumbra, Inc.

{
  "main_header": {
    "sid": 1159036,
    "name": "Penumbra, Inc.",
    "stock_name": "Penumbra, Inc.",
    "full_name": "Penumbra, Inc.",
    "name_url": "stocks-analysis/penumbra-inc",
    "exchange": 1,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "359.26",
    "chg": 102.77,
    "chgp": "40.07%",
    "dir": 1,
    "prev_price": "256.49",
    "mcapval": "14,007.53",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US70975L1070",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "552.51 k",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/penumbra-inc-1159036-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Penumbra, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-penumbra-inc-overvalued-or-undervalued-3723363",
        "imagepath": "",
        "date": "2025-11-23 11:11:02",
        "description": "As of 21 November 2025, the valuation grade for Penumbra, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, which are substantially higher than industry norms. In comparison, peers such as Hologic, Inc. have a P/E ratio of 21.83 and an EV to EBITDA of 14.71, showcasing a stark contrast in valuation metrics.\n\nDespite Penumbra's strong recent performance, with a year-to-date return of 21.47% compared to the S&P 500's 12.26%, the elevated valuation ratios suggest that the stock may not be justified at its current price level. The combination of these factors reinforces the conclusion that Penumbra, Inc. is overvalued in the current market...."
      },
      {
        "title": "Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/penumbra-inc-stock-hits-52-week-low-at-usd-22126-3671494",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PenumbraInc_priceRelatedfactors_3671494.png",
        "date": "2025-11-04 17:52:08",
        "description": "Penumbra, Inc. has reached a new 52-week low of USD 221.26, reflecting recent market volatility. Despite this, the company has achieved a one-year performance of 20.28%, slightly surpassing the S&P 500. With a market cap of USD 11,138 million, Penumbra exhibits a P/E ratio of 84.00 and a return on equity of 11.41%."
      },
      {
        "title": "Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/penumbra-inc-sees-valuation-grade-shift-from-very-expensive-to-expensive-3649064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PenumbraInc_valuationdot_3649064.png",
        "date": "2025-10-27 15:53:14",
        "description": "Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at $252.99. Over the past year, it achieved a 22.48% stock return, surpassing the S&P 500. Key metrics indicate a premium valuation compared to industry peers."
      }
    ],
    "total": 19,
    "sid": "1159036",
    "stock_news_url": "https://www.marketsmojo.com/news/penumbra-inc-1159036"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Penumbra, Inc. overvalued or undervalued?

2025-11-23 11:11:02

As of 21 November 2025, the valuation grade for Penumbra, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its high valuation ratios, including a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, which are substantially higher than industry norms. In comparison, peers such as Hologic, Inc. have a P/E ratio of 21.83 and an EV to EBITDA of 14.71, showcasing a stark contrast in valuation metrics. Despite Penumbra's strong recent performance, with a year-to-date return of 21.47% compared to the S&P 500's 12.26%, the elevated valuation ratios suggest that the stock may not be justified at its current price level. The combination of these factors reinforces the conclusion that Penumbra, Inc. is overvalued in the current market....

Read full news article

Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26

2025-11-04 17:52:08

Penumbra, Inc. has reached a new 52-week low of USD 221.26, reflecting recent market volatility. Despite this, the company has achieved a one-year performance of 20.28%, slightly surpassing the S&P 500. With a market cap of USD 11,138 million, Penumbra exhibits a P/E ratio of 84.00 and a return on equity of 11.41%.

Read full news article

Penumbra, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

2025-10-27 15:53:14

Penumbra, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at $252.99. Over the past year, it achieved a 22.48% stock return, surpassing the S&P 500. Key metrics indicate a premium valuation compared to industry peers.

Read full news article

View All News